AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$TMO

CASPER MARC N sold $172K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $627.05 ($625.41–$628.74, $0.17M total) across 4 trades on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 26, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate price impact.

02

Market read

Provides fresh insider transaction data for traders monitoring executive activity.

03

What to watch

Potential tax planning or portfolio rebalancing may drive the transaction, not company performance.

Relevance 3/10Novelty 4/10Timing: post‑market 2026-08-24

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

CEO Casper Marc N sold 275 shares for $172,438 via a 10b5-1 plan on 2026-08-24

Expected impact

Potential slight downward pressure, likely within normal volatility range

Evidence & confidence

The sale represents ~0.2% of the insider's post‑transaction holdings and is disclosed under a pre‑arranged plan, limiting immediate market reaction.

Market effects

Sector

Minimal impact on the life‑sciences equipment sector; insider sales are routine.

Regional

No significant regional effect; the filing is specific to Thermo Fisher.

Global

Limited global relevance; only relevant to investors tracking Thermo Fisher.

Counterpoint

What could challenge this read

The sale could be unrelated to company outlook, as 10b5‑1 plans are pre‑scheduled.

Key entities

  • Company
    Thermo Fisher Scientific Inc.

    US‑listed life‑sciences equipment and services provider (ticker TMO).

  • Individual
    Casper Marc N

    Chairman & CEO of Thermo Fisher Scientific.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TMO insider trading history →

Related articles

OCT 24
$TMOHighAI 8/10

Thermo Fisher Q3 Revenue Hits $12.14 Billion as Shares Touch Record $705 — BigGo Finance

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.

finance.biggo.com3 min
OCT 22
$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

finance.yahoo.com1 min
OCT 22
$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.

biospectrumasia.com2 min